BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Daxokafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Daxokafusp alfa\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05584670-2720@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Daxokafusp alfa: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Daxokafusp alfa\, phase 1/2.\nStudy: A First-in-human\, Dose Es
 calation and Dose Expansion Study of SAR445877 in Adult Participants With 
 Advanced Solid Tumors\nEstimated primary completion: 19 January 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133425-2720@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Daxokafusp alfa: Phase 2 readout est. (NCT07133425)
DESCRIPTION:Daxokafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory 
 Non-small Cell Lung Cancer\nEstimated primary completion: 1 February 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alfa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07133425
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692204-2720@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20280802
DTEND;VALUE=DATE:20280803
SUMMARY:Daxokafusp alfa: Phase 2 readout est. (NCT07692204)
DESCRIPTION:Daxokafusp alfa\, phase 2.\nStudy: A Dose Optimization/Expansio
 n Study of SAR445877 in Adult Chinese Participants With Advanced Gastric o
 r Gastroesophageal Junction Cancer\nEstimated primary completion: 2 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alf
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 692204
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500298-2720@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20301227
DTEND;VALUE=DATE:20301228
SUMMARY:Daxokafusp alfa: Phase 1 readout est. (NCT07500298)
DESCRIPTION:Daxokafusp alfa\, phase 1.\nStudy: Phase 1 Study Of SAR445877 I
 n Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Mic
 rosatellite Stable Metastatic Colorectal Cancer\nEstimated primary complet
 ion: 27 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/daxokafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07500298
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
